Rilonacept in Cardiac Sarcoidosis
Recruiting Phase 2 NCT06660732
Study Description
Evaluating the effect of rilonacept on reducing inflammation in the heart caused by sarcoidosis
Study Details
- Registry ID:
- NCT06660732
- Conditions:
- Cardiac Sarcoidosis
- Phase:
- Phase 2
- Target Enrollment:
- 60 participants
- Start Date:
- Age Range:
- 18–80 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Johns Hopkins University
Baltimore, Maryland, United States -
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.